The 1st episode of 2021 covers 5 FDA updates from December 2020
-Pralsetinib for RET-mutated medullary thyroid cancer
-The new HER2-targeting margetuximab
-Selinexor and the Boston study
-Relugolix, an oral GnRH antagonist
-Adjuvant osimertinib approved (ADAURA)
